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Peptide, and Amino-Terminal Pro-B-Type
Natriuretic Peptide in Patients With Chronic Heart Failure
Prediction of Death at Different Stages of the Disease
Stephanie Neuhold, MD,* Martin Huelsmann, MD,* Guido Strunk, PHD,‡ Brigitte Stoiser, MD,†
Joachim Struck, PHD,§ Nils G. Morgenthaler, MD,§ Andreas Bergmann, PHD,§ Deddo Moertl, MD,*
Rudolf Berger, MD,* Richard Pacher, MD*
Vienna, Austria; and Hennigsdorf, Germany
Objectives This study sought to evaluate the predictive value of copeptin over the entire spectrum of heart failure (HF) and
compare it to the current benchmark markers, B-type natriuretic peptide (BNP) and N-terminal pro-B-type natri-
uretic peptide (NT-proBNP).
Background Vasopressin has been shown to increase with the severity of chronic HF. Copeptin is a fragment of pre–
pro-vasopressin that is synthesized and secreted in equimolar amounts to vasopressin. Both hormones have a
short lifetime in vivo, similar to BNPs, but in contrast to vasopressin, copeptin is very stable in vitro. The predic-
tive value of copeptin has been shown in advanced HF, where it was superior to BNP for predicting 24-month
mortality.
Methods This was a long-term observational study in 786 HF patients from the whole spectrum of heart failure (New York
Heart Association [NYHA] functional class I to IV, BNP 688  948 pg/ml [range 3 to 8,536 pg/ml], left ventricu-
lar ejection fraction 25  10% [range 5% to 65%]).
Results The NYHA functional class was the most potent single predictor of 24-month outcome in a stepwise Cox regres-
sion model. The BNP, copeptin, and glomerular filtration rate were related to NYHA functional class (p  0.0001
for trend). Copeptin was the most potent single predictor of mortality in patients with NYHA functional class II (p
 0.0001) and class III (p  0.0001). In NYHA functional class IV, the outcome of patients was best predicted
by serum sodium, but again, copeptin added additional independent information.
Conclusions Increased levels of copeptin are linked to excess mortality, and this link is maintained irrespective of the clinical
signs of severity of the disease. Copeptin was superior to BNP or NT-proBNP in this study, but the markers seem
to be closely related. (J Am Coll Cardiol 2008;52:266–72) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.050a
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the use of natriuretic peptides such as atrial natriuretic
eptide (ANP) and brain natriuretic peptide (BNP) and
heir precursors N-terminal pro-B-type natriuretic peptide
NT-proBNP) and N-terminal pro-atrial natriuretic pep-
ide (NT-proANP) for the assessment of cardiovascular risk
s firmly established in cardiovascular guidelines (1). Higher
evels of natriuretic peptides have been shown to be associ-
rom the *Department of Cardiology and the †Department of Infectious Diseases,
edical University of Vienna, Vienna, Austria; ‡Research Institute for Health Care
anagement and Economics, University of Economics and Business Administration,
ienna, Austria; and §B.R.A.H.M.S. AG, Hennigsdorf, Germany.p
Manuscript received December 20, 2007; revised manuscript received March 10,
008, accepted March 18, 2008.ted with advanced patient age, renal impairment, cardiac
rrhythmias, and systolic and diastolic dysfunction (2).
hese peptides therefore reflect an integral of risk factors
esulting in the current functional cardiovascular status of
ndividual patients, making them an invaluable tool for risk
tratification (3–5).
Vasopressin, unlike the natriuretic peptides, is an antidi-
retic and vasoconstricting hormone (6,7). Regulation of
ree water reabsorption, body fluid osmolarity, blood vol-
me, vascular tone, and probably cell proliferation are
ediated via interactions with specific receptors termed V2
renal) and V1a (vascular). There are robust data showing
hat vasopressin is related to the severity of heart failure and
robably to outcome as well (8–10). However, vasopressin is
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July 22, 2008:266–72 Copeptin in Chronic Heart Failureifficult to measure because it is a hormone that is unstable,
onsiderably bound to platelets, and rapidly cleared (11).
Copeptin is a fragment of pre–pro-vasopressin that is
ynthesized and secreted in equimolar amounts to vasopres-
in. Its advantages are its long stability and that it can be
uickly and reliably measured in unprocessed plasma or
erum. The predictive value of this marker has been shown
n critically ill patients (12–15), in coronary artery disease
16), and in the context of advanced heart failure (17).
Little is known about the role of the vasopressin system as
easured by its surrogate copeptin over the entire clinical
pectrum of heart failure because research in this area so far
as focused on advanced heart failure. In this study we
nvestigated the predictive value of copeptin over the entire
pectrum of heart failure.
ethods
e included 786 patients from several clinical trials in this
ong-term observational study. The study population repre-
ents the entire spectrum of severity of heart failure. At
ndex time, clinical variables were obtained. Blood was
rawn in every patient. Left ventricular ejection fraction
LVEF) was determined by echocardiography or techne-
ium scintigraphy. In a subset of 177 patients, right heart
atheterization was performed.
At follow-up, patients were treated as clinically appropri-
te. Most patients were cared for in our tertiary care heart
ailure outpatient clinic. The follow-up period was 2 years.
he end point was defined as all-cause mortality within 24
onths. If patients failed to attend their scheduled visits,
urvival status was obtained either by telephone calls or by
he Austrian Central Office of Civil Registration (Zentrales
elderegister Österreich). The study was conducted in
ccordance with the Helsinki II declaration and approved by
he ethics committee of our institution. All participants gave
ritten informed consent.
eurohumoral measurements. At index evaluation, blood
amples were taken from an antecubital vein. The samples
ere centrifuged, transferred into chilled tubes, and placed
n ice. Plasma was frozen at 20°C until it was assayed.
he BNP level was determined using a commercially
vailable rapid test purchased from Biosite Diagnostics (San
iego, California). The NT-proBNP level was determined
sing a commercially available test purchased from Roche
iagnostics (Basel, Switzerland).
Determination of copeptin (C-terminal pro-vasopressin)
n the chemiluminescence/coated-tube format was per-
ormed as described (18). Briefly, the tubes were coated
ith a purified sheep polyclonal antibody raised against a
eptide representing positions 132 to 147 of pre–pro-
asopressin. A purified sheep polyclonal antibody raised
gainst a peptide representing positions 149 to 164 of
re–pro-vasopressin was labeled with MACN-akridinium-
.hydroxysuccinimide-ester and used as tracer. Dilutions of apeptide representing positions
32 to 164 of pre–pro-arginine
asopressin in normal horse se-
um served as standards. The im-
unoassay was performed by in-
ubating 50 l of samples/
tandards and 200 l of tracer in
oated tubes for 2 h at room tem-
erature. The tubes were washed
times with 1 ml of LUMItest
ash solution (B.R.A.H.M.S.
G, Hennigsdorf, Germany),
nd bound chemiluminescence
as measured with an LB952T
uminometer (Berthold, Bad
ildbach, Germany).
tatistical analysis. Continuous
ariables are expressed as mean
standard deviation. To test
ifferences in characteristics be-
ween survivors and nonsurvi-
ors, Student t tests are used. The t test statistics require
ormal distributed differences of sample means, which is
xpectable for large samples (sum of both samples exceeding
00) due to the central limit theorem. This is the case for
ur data. To avoid problems arising from inhomogeneous
ariances, we use the t test based on the Welch formula.
ifferences among New York Heart Association (NYHA)
unctional classes were tested using 1-factorial analysis of
ariance and the t test based contrast statistics. Correlations
f BNP, copeptin, and glomerular filtration rate (GFR)
ith NYHA functional class were calculated based on the
pearman rank correlation.
Categorical variables are given as number and percent.
ifferences between dichotomous variables (e.g., gender)
ere calculated using the Fisher exact test. Differences in
he distribution of NYHA functional classes between sur-
ivors and nonsurvivors were tested using a chi-square test.
A stepwise logistic regression model was performed to
dentify independent predictors of copeptin. A stepwise Cox
egression model was performed to identify independent
redictors of outcome. Both models are based on a stepwise
lgorithm, with the p value set at 0.05 for entering and 0.1
or exclusion. All results of the regression model were
resented using odds ratios EXP (B). Odds ratios were
iven for increase per unit. Receiver-operator characteristic
ROC) analysis was calculated to assess the utility of
opeptin to distinguish between survivors and nonsurvivors.
he 24-month survival was calculated using the Kaplan-
eier method, in which patients were divided into quartiles
f copeptin plasma levels. Differences among Kaplan-Meier
urves were tested using a log-rank test. A value of p 0.05
as considered significant in all analyses; SPSS version 15.0
SPSS Inc., Chicago, Illinois) was used for all statistical
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
BNP  brain natriuretic
peptide
GFR  glomerular filtration
rate
LVEF  left ventricular
ejection fraction
NT-proANP  N-terminal
pro-atrial natriuretic
peptide
NT-proBNP  N-terminal
pro-B-type natriuretic
peptide
NYHA  New York Heart
Association
ROC  receiver-operator
characteristicnalyses.
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Copeptin in Chronic Heart Failure July 22, 2008:266–72esults
he total study population comprised 786 patients. Char-
cteristics of this population represent the whole spectrum
f heart failure based on systolic dysfunction (NYHA
unctional classes I through IV, BNP 688  948 pg/ml
range 3 to 8,536 pg/ml], NT-proBNP 494  724 pg/ml
range 2 to 8,877 pg/ml], copeptin 18.9  24.2 pmol/l
range 0.7 to 224 pmol/l], LVEF 25  10% [range 5% to
5%]). The mean age of our population was 57  11 years;
he gender ratio (male/female) was 81%:19%. The BNP and
opeptin levels escalated with increasing NYHA functional
lass and decreasing glomerular filtration rate (Fig. 1). This
as significant for trend for all 4 variables (p  0.0001).
ifty percent of patients had a history of hypertension, 27%
ad signs of kidney dysfunction (GFR 60 ml/min), 22%
ad diabetes mellitus, and 40% had ischemic heart disease.
he majority of patients (79%) were in sinus rhythm; the
atients’ mean weight was 80 15 kg. Mean blood pressure
alues were 117  23 mm Hg systolic and 74  14 mm Hg
iastolic. Heart rate was 75  16 beats/min on average.
eventy percent of the patients were treated with a beta-
locker, 94% with a renin-angiotensin-aldosterone system
ntagonist, and 31% with an aldosterone antagonist; 66% of
atients received furosemide requiring a mean dose of 75 
4 mg. The mean duration of the observation period was
5.8  6.6 months (range 0.1 to 24 months). At the
ollow-up investigation, 233 (30%) patients had died. The
atients’ clinical characteristics dependent on outcome are
resented in Table 1.
orrelations between copeptin and several dependent
ariables. Copeptin significantly correlated with GFR (r
0.343; p  0.0001), sodium (r  0.165; p  0.0001),
ystolic blood pressure (r  0.076; p  0.034), and the
resence of leg edema (r  0.187; p  0.0001) in the
Figure 1 Box Plots of Plasma BNP, Copeptin, and GFR
Median levels of BNP, copeptin, and GFR depending on NYHA functional class.
BNP  brain natriuretic peptide; GFR  glomerular filtration rate; NYHA  New Yontire population. Whereas this held true for GFR through-
ut all NYHA functional classes (I: r  0.347; p 
.0001, II: r  0.377; p  0.0001, III: r  0.290; p 
.0001, IV: r  0.290; p  0.0001), systolic blood
ressure did not reach statistical significance in distinct
YHA functional classes. Sodium only reached statistically
ignificant correlations in advanced stages (III: r  0.147;
 0.007, IV: r  0.201; p  0.012). Interestingly the
ccurrence of leg edema only correlated in NYHA func-
ional class I with copeptin, but this correlation was very
trong (r  0.568; p  0.0001).
In a subset of 77 patients in NYHA functional class III
nd 100 patients in NYHA functional class IV, right heart
atheterization was performed. Regarding patients in
YHA functional class III, there was a bivariate correlation
ith copeptin and cardiac index (r2  0.228; p  0.046),
ulmonary capillary wedge pressure (r  0.221; p 
.053), pulmonary vascular resistance index (r  0.271;
 0.017), and systemic vascular resistance index (r 
0.277; p  0.015). Copeptin in patients in NYHA
unctional class IV only correlated with pulmonary vascular
esistance index (r  0.253; p  0.011).
tepwise Cox regression analysis to predict death within
4 months. ENTIRE POPULATION. Of all variables ana-
yzed, NYHA functional class (p  0.0001), GFR (p 
.0001), systolic blood pressure (p  0.006), and gender
p  0.014) predicted death in the entire population. The
YHA functional class gave the most potent single infor-
ation (Table 2). The models were similar if BNP or
T-proBNP was entered (data only shown for BNP).
ICHOTOMIZED BY NYHA FUNCTIONAL CLASS. Because
YHA functional class was the strongest predictor, we used
his variable to dichotomize the severity of the disease to
nalyze the predictive power of copeptin at different stages
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July 22, 2008:266–72 Copeptin in Chronic Heart Failuref heart failure. For patients in NYHA functional class I,
he low mortality precluded statistical analysis. Copeptin
as the most potent single predictor of mortality in patients
ith NYHA functional classes II (p 0.0001) and III (p
.0001). For patients with NYHA functional class IV,
odium levels gave the most potent single information (p 
.005), with stepwise additional information provided by
ender (p 0.0001), GFR (p 0.0001), and copeptin (p
.022) (Table 3). The models were similar if BNP or
T-proBNP was entered (data only shown for BNP).
tepwise logistic regression with copeptin as a dependent
ariable. To better understand the information provided
y the respective individual values of copeptin, we per-
ormed a regression analysis with copeptin as a dependent
ariable. We found that BNP (p  0.0001) was the best
redictor of copeptin values, followed by GFR (p 
.0001). Age and gender were additional influencing
actors (both p  0.0001). This strong relationship
etween copeptin, BNP, and GFR held true over every
istinct NYHA functional class.
aplan-Meier analysis. Using a Kaplan-Meier model for
-year survival, patients had a decreasing survival rate
ependent on quartiles of copeptin distribution (p 
.0001) (Fig. 2). This held true for subanalysis of NYHA
Patients’ Clinical Characteristics
Table 1 Patients’ Clinical Characteristics
Survivors (n 
Age (yrs) 56 12
Female gender (%) 107 (19%)
LVEF (%) 26 11
NYHA functional class I/II/III/IV (%) 15.6/27.3/43.0
SBP (mm Hg) 120 24
Sodium (mmol/l) 139 5
GFR (ml/min) 82 30
BMI (kg/m2) 26.8 4.3
BNP (pg/ml) 551 890
Copeptin (pmol/l) 15.5 9.4
All differences tested using t test, except those noted by footnote sym
BMI  body mass index; BNP  brain natriuretic peptide; GFR  g
significant; NYHA  New York Heart Association; SBP  systolic blood
ingle-Predictor and Multivariable Stepwise Cox Regression Analys
Table 2 Single-Predictor and Multivariable Stepwise Cox Regre
Single-Predictor Model for Survival
Odds Ratio 95% Confidence Interval
BNP (pg/ml) 1.0003 1.0002–1.0003
Copeptin (pmol/l) 1.0101 1.0069–1.0133
Age (yrs) 1.0205 1.0085–1.0326
NYHA functional class 1.6963 1.4527–1.9808
GFR (ml/min) 0.9871 0.9824–0.9918
LVEF (%) 0.9706 0.9562–0.9852
SBP (mm Hg) 0.9820 0.9755–0.9885
Sodium (mmol/l) 0.9673 0.9553–0.9795
BMI (kg/m2) 0.9742 0.9443–1.0051
Female gender (%) 1.3312 0.9253–1.9253bbreviations as in Table 1.unctional classes I (p  0.02), II (p  0.02), and III (p 
.0001), but not for class IV.
OC curves. The area under the ROC curve with respect
o 2-year all-cause mortality was 0.711 for BNP and 0.711
or copeptin. The predictive power increased to an area
nder the ROC curve of 0.744 if both variables were added
n one model (Fig. 3).
iscussion
n the present study we have shown a strong and indepen-
ent correlation between plasma copeptin levels and all-
ause mortality in a cohort of patients with chronic heart
ailure. Patients with increased levels of copeptin had a
orse prognosis. This held true over the entire cohort of
ymptomatic patients (NYHA functional class II, III, and
V). Increased levels of copeptin were best predicted by
atriuretic peptides and kidney function.
rognostic implications. The prognostic role of neurohu-
oral markers in heart failure is of great interest and clinical
mportance. Natriuretic peptides such as ANP and BNP or
heir inactive N-terminal precursors NT-proBNP or NT-
roANP are currently certainly the benchmark against
hich all novel biomarkers must be measured.
Nonsurvivors (n  233) p Value (2-Tailed)
59 10 0.0003
34 (15%) NS*
23 9 0.0001
6.4/16.4/43.8/33.0 0.0001†
110 18 0.0001
137 5 0.0001
69 29 0.0001
26.3 4 NS
1,018 1,013 0.0001
27.2 26.9 0.0001
Fisher exact test; †chi-square test.
lar filtration rate; LVEF  left ventricular ejection fraction; NS  not
re.
24-Month Mortality for Various Clinical Variables
Analysis for 24-Month Mortality for Various Clinical Variables
Multivariable Model for Survival
Value Odds Ratio 95% Confidence Interval p Value
0.0005
0.0005
0.0008
0.0005 1.5038 1.2683–1.7830 0.0005
0.0005 0.9881 0.9827–0.9936 0.0005
0.0001
0.0005 0.9899 0.9828–0.9970 0.0055
0.0005
0.1009
0.1232 1.6671 1.1092–2.5057 0.0140553)
/14.1
bols. *is for
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Copeptin in Chronic Heart Failure July 22, 2008:266–72In an earlier article we showed that copeptin is a reliable
utcome predictor in advanced heart failure, at least com-
arable to BNP (17). In this study we evaluated the
redictive aptitude of copeptin for the entire spectrum of
eart failure, including patients with NYHA functional
lass I to IV, BNP levels from 3 to 8,536 pg/ml, and the
ntire spectrum of progressive kidney dysfunction.
The most potent independent, single prediction was
rovided by the clinical marker NYHA functional class,
hich was even superior to BNP. An explanation for this
urprising finding may be that this investigation was done at
tertiary care center with great experience in heart failure.
he expertise of a clinical assessment undertaken in a heart
ailure unit is most likely not applicable to the general
etting, where laboratory markers are more objective.
Figure 2 Quartiles of Copeptin
Kaplan-Meier plots: survival in patients
grouped according to quartiles of plasma copeptin.
tepwise Cox Regression Analysis for Predictingurvival Depending on NYHA Functional Class
Table 3 Stepwise Cox Regression Analysis for PredictingSurvival Depending on NYHA Functional Class
Odds Ratio 95% Confidence Interval p Value
NYHA functional class II
Copeptin (pmol/l) 1.0138 1.0066–1.0209 0.0001
LVEF (%) 0.9584 0.9218–0.9965 0.0327
NYHA functional class III
Copeptin (pmol/l) 1.0098 1.0031–1.0165 0.0039
Age (yrs) 1.0378 1.0147–1.0614 0.0012
SBP (mm Hg) 0.9850 0.9739–0.9962 0.0086
NYHA functional class IV
Sodium (mmol/l) 0.9272 0.8802–0.9767 0.0044
Female gender (%) 3.720 1.6995–8.1951 0.0010
GFR (ml/min) 0.9805 0.9694–0.9917 0.0007
Copeptin (pmol/l) 0.9864 0.9752–0.9977 0.0181
bbreviations as in Table 1.iBecause NYHA functional class was the strongest pre-
ictor, we used this variable to dichotomize the severity of
he disease to analyze the predictive power of copeptin at
ifferent stages of heart failure. Copeptin was independently
elated to mortality in each symptomatic stage of heart
ailure; it was most compelling in NYHA functional classes
I and III. This is an important finding because NYHA
unctional classes II and III, the intermediate classes, are
ore difficult to judge in the ambulatory setting than the
ore obvious NYHA functional classes I and IV.
For asymptomatic patients (NYHA functional class I),
he event rate was too low to provide any information from
ur cohort. Recent data presented by Khan et al. (16) show
hat copeptin is a powerful predictor of outcome after acute
yocardial infarction. Because myocardial infarction can be
een as stage A to B heart failure, it can be presumed that
opeptin might also provide some predictive information in
his early stage.
For patients in the most severe stage of heart failure,
YHA functional class IV, copeptin provided independent
dditional information, but was inferior to sodium levels
nd especially GFR. Again, BNP provided no additional
nformation. It can be presumed that in the case of end-
tage heart failure, fluid-regulating hormones might be of
imited value for prognosis because kidney function as the
orphologic substrate of fluid regulation becomes para-
ount. The importance of kidney function as a prognostic
arker is well described and might concern especially severe
eart failure patients (19). Considering the whole system of
iuretic and antidiuretic hormones as well as kidney func-
ion in one model could probably provide some additional
Figure 3 ROC for 24-Month Survival
Area under receiver-operator characteristic (ROC) curves for 24-month survival
for copeptin, BNP, and copeptin plus BNP. AUC  area under the receiver-
operator characteristic curve; other abbreviations as in Figure 1.nformation.
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July 22, 2008:266–72 Copeptin in Chronic Heart FailureRegression analysis revealed a strong interdependence
etween this triad of fluid homoeostasis. It could be
ypothesized that an uncoupling of the whole system
orresponds to an advanced dysregulation with an increasing
isk for future events, as already described in other patterns
20). This would imply that in the future, one marker could
ot be sufficient to provide the full prognostic information
f the fluid-regulating system in heart failure. More sophis-
icated models are warranted to test this hypothesis.
linical implications. What makes vasopressin and its
recursor copeptin exciting for heart failure research today is
ot only the prognostic information provided by these
arkers, but also the role of vasopressin blockade as a
otential new therapeutic target. Newly developed agents
argeting vasopressin receptors are under investigation and
ight result in a novel adjunct treatment of both acute and
hronic heart failure (21–24).
V2 antagonists are viewed as a new class of diuretics,
ermed “aquaretics” because of their ability for free water
iuresis without an accompanying significant depletion of
lectrolytes or worsening of renal function (24,25). Al-
hough excellent results were found based on their diuretic
roperties, no survival benefit could be shown (26,27).
Only a post hoc analysis of an earlier trial suggested a
urvival benefit for patients with severe heart failure (22).
his is in accordance with our previous data, in which
opeptin was markedly increased especially in this popula-
ion (17).
Our current data confirm that increased levels of copeptin
re linked to excess mortality, and this link is maintained
rrespective of the clinical signs of severity of the disease.
opeptin could therefore emerge as an independent marker
o identify heart failure patients from the whole spectrum of
he disease, who could benefit from adjunct therapy with a
2 antagonist. This could in the future permit a more
ailored therapy for heart failure patients. This hypothesis
hould be proven in further studies.
In advanced stages of heart failure (NYHA functional
lasses III and IV), we performed right heart catheterization
n a subpopulation of patients and found a significant
orrelation between copeptin and indexes of vascular resis-
ance. This offers some evidence for the importance of V1a
eceptor signaling in heart failure, which directly affects the
yocyte and vasoconstriction. This could provide a ratio-
ale to pursue V1a antagonists in chronic heart failure.
tudy limitations. During follow-up, therapy was adapted
s clinically appropriate and according to guidelines. Thus,
treatment effect during follow-up cannot be excluded.
atients investigated in our study were younger and have
ore hypertension and less coronary artery disease than in
ther large clinical studies. This might be the result of this
nvestigation being performed at a tertiary care unit known
o care for younger patients. The large number of patients
ith hypertensive cardiomyopathy (compared with other
tudies) might be based on the growing awareness about this
isease entity in recent years.onclusions
opeptin is a novel predictive marker in chronic systolic
eart failure, not only in advanced but also in less severe
tages. Copeptin was superior to BNP in this study, but
oth markers seem to be closely related.
eprint requests and correspondence: Dr. Martin Huels-
ann, Medical University of Vienna, Department of Cardiol-
gy, Waehringer Guertel 18-20, 1090 Vienna, Austria. E-mail:
artin.huelsmann@meduniwien.ac.at.
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